GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016538 describes a molecular function that modulates the activity of cyclin-dependent protein serine/threonine kinases (CDKs), enzymes regulated through association with cyclins and other proteins.
• Cyclins and other regulatory subunits are the primary proteins that carry this activity, binding to CDKs to control cell cycle progression and transcription.
• Dysregulation of CDK regulators is linked to cancer, making them promising targets for therapy.
• CDK7, a member of the CDK family, requires a cyclin partner for activity and is a target for inhibitor development [3,7].
• CDK1, beyond its canonical cell cycle role, has additional functions that are being uncovered.
• Studying GO:0016538 involves methods such as knockout, point mutation, knock-in, and overexpression models to dissect regulatory mechanisms.
Description
Cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538) is a molecular function that governs the activity of cyclin-dependent kinases (CDKs), a family of enzymes central to cell cycle control and transcription. This activity is essential for proper progression through the cell cycle, as CDKs require association with regulatory subunits, such as cyclins, to become active. The precise regulation of CDK activity ensures that cell division occurs accurately and in response to appropriate signals. Dysregulation of this regulatory function can lead to uncontrolled cell proliferation, a hallmark of cancer. Therefore, understanding the mechanisms and components of GO:0016538 is critical for both basic cell biology and therapeutic development. Researchers study this term to identify how cyclins and other regulators modulate CDK activity, and to explore how perturbations contribute to diseases like cancer [1,2]. The availability of CRISPR-based tools now allows precise genetic manipulation of genes encoding these regulators, enabling functional studies that were previously challenging.
cyclin-dependent protein serine/threonine kinase regulator activity At A Glance
| GO ID | GO:0016538 |
|---|---|
| GO term | cyclin-dependent protein serine/threonine kinase regulator activity |
| Ontology | molecular_function |
| Synonym | cyclin, cyclin-dependent protein kinase, intrinsic regulator activity, cyclin-dependent protein kinase regulator activity, G1/S-specific cyclin, G2/M-specific cyclin |
| Major function | Modulates the activity of cyclin-dependent protein serine/threonine kinases |
| Definition | Modulates the activity of a cyclin-dependent protein serine/threonine kinase, enzymes of the protein kinase family that are regulated through association with cyclins and other proteins. |
| Related kinases | CDKs (e.g., CDK1, CDK7, CDK20) |
| Related regulators | Cyclins (e.g., cyclin B, cyclin H) |
What Is GO:0016538?
GO:0016538, cyclin-dependent protein serine/threonine kinase regulator activity, is defined as a molecular function that modulates the activity of a cyclin-dependent protein serine/threonine kinase. These kinases are enzymes of the protein kinase family that are regulated through association with cyclins and other proteins. In essence, this term captures the activity of proteins that bind to and regulate CDKs, either activating or inhibiting them, thereby controlling key cellular processes such as cell cycle progression and transcription.
Why Is cyclin-dependent protein serine/threonine kinase regulator activity Important in Cell Biology?
GO:0016538 is fundamental to the regulation of the cell cycle and transcription, processes that are frequently hijacked in human diseases, especially cancer. Because CDK regulators determine when and where CDKs are active, they are attractive targets for therapeutic intervention. For example, inhibitors of CDK7, a kinase activated by cyclin H, are being developed as anticancer agents. Moreover, understanding the regulatory mechanisms can reveal biomarkers and resistance pathways. The term also encompasses non-canonical regulators, such as CDK20/LF2, which activates CDKL5 in ciliary length control. Thus, studying GO:0016538 provides insights into both normal physiology and disease pathogenesis.
• Controls cell cycle progression and cell division.
• Regulates transcription by modulating CDK7 activity [3,7].
• Dysregulation leads to cancer and other proliferative disorders.
• Provides targets for small-molecule inhibitors in cancer therapy [1,3].
• Involved in specialized functions like ciliary length control.
• Can be modulated by extracellular signals, e.g., fibronectin receptor.
• Viral infections can alter CDK activity, as seen with herpes simplex virus type 2.
• Structural studies inform rational drug design.
• CDK1 has roles beyond cell cycle, expanding the functional repertoire.
• CRISPR screens can identify novel regulators and therapeutic targets.
What Happens During cyclin-dependent protein serine/threonine kinase regulator activity?
Binding of Regulatory Subunits to CDKs
In simple terms: Regulator proteins attach to CDK enzymes to control their activity.
The activity described by GO:0016538 begins with the physical association of a regulatory subunit, typically a cyclin, with a cyclin-dependent kinase (CDK). This binding induces conformational changes in the CDK that are necessary for its catalytic function. For example, cyclin H binds to CDK7 to form the CDK-activating kinase (CAK) complex, which phosphorylates other CDKs to regulate the cell cycle. The specificity of these interactions ensures that CDKs are activated at the right time and place.
Activation or Inhibition of Kinase Activity
In simple terms: Once bound, the regulator can turn the CDK on or off.
Upon binding, the regulatory subunit can either activate or inhibit the kinase activity of the CDK. Activation often involves rearrangement of the catalytic site and alignment of key residues for phosphotransfer. In contrast, some regulators, such as the CKIs (cyclin-dependent kinase inhibitors), can block substrate access or distort the active site. The balance between activating and inhibitory regulators determines the net CDK activity, which is crucial for orderly cell cycle transitions.
Phosphorylation of Downstream Substrates
In simple terms: The active CDK then adds phosphate groups to target proteins.
Once activated, the CDK phosphorylates serine or threonine residues on specific substrate proteins. These substrates include retinoblastoma protein (Rb), which when phosphorylated releases E2F transcription factors to drive S-phase gene expression. The phosphorylation events orchestrated by CDK-regulator complexes propagate signals that control DNA replication, mitosis, and transcription. The specificity of substrate recognition is often dictated by the regulatory subunit, which can target the CDK to particular substrates or subcellular locations.
Integration with Cellular Signals
In simple terms: External and internal signals influence how regulators work.
The activity of CDK regulators is not constitutive; it is modulated by various signaling pathways. For instance, the fibronectin receptor can modulate CDK activity, linking extracellular matrix adhesion to cell cycle progression. Additionally, viral infections, such as herpes simplex virus type 2, can alter CDK activity, presumably to create a favorable environment for viral replication. These examples illustrate how GO:0016538 integrates diverse cellular inputs to fine-tune CDK function.
Key Genes Involved in GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
The following genes encode proteins that possess or regulate cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCNA1 | Cyclin A1, activates CDK2 for S phase and CDK1 for mitosis | Cell cycle regulation, cancer |
| CCNB1 | Cyclin B1, activates CDK1 for mitotic entry | Mitosis, cancer |
| CCND1 | Cyclin D1, activates CDK4/6 for G1 progression | Cancer, cell cycle |
| CCNE1 | Cyclin E1, activates CDK2 for G1/S transition | Cancer, cell cycle |
| CCNH | Cyclin H, activates CDK7 in CAK complex | Transcription, cell cycle |
| CDK1 | Cyclin-dependent kinase 1, key mitotic kinase | Cell cycle, cancer |
| CDK7 | Cyclin-dependent kinase 7, CAK catalytic subunit | Transcription, cancer [3,7] |
| CDK20 | Cyclin-dependent kinase 20, activates CDKL5 | Ciliary length control |
| CDKL5 | Cyclin-dependent kinase-like 5, activated by CDK20 | Ciliary function |
| CKS1B | CDK regulatory subunit 1, binds CDKs | Cell cycle, cancer |
| CKS2 | CDK regulatory subunit 2, binds CDKs | Cell cycle, cancer |
| RING1 | Really interesting new gene 1, potential regulator | Not well characterized |
| MNAT1 | Menage a trois 1, part of CAK complex | Transcription, cell cycle |
| XPC | Xeroderma pigmentosum group C, potential regulator | DNA repair, transcription |
| TFPB1 | Transcription factor B1, potential regulator | Not well characterized |
| CCNK | Cyclin K, activates CDK9 for transcription | Transcription elongation |
| CCNT1 | Cyclin T1, activates CDK9 for HIV Tat transactivation | Transcription, viral replication |
How Is cyclin-dependent protein serine/threonine kinase regulator activity Regulated?
The activity of cyclin-dependent protein serine/threonine kinase regulators is itself tightly regulated at multiple levels. Transcriptional control of cyclin genes ensures that they are expressed in a cell-cycle-dependent manner. Post-translational modifications, such as phosphorylation and ubiquitination, control the stability and localization of both cyclins and CDKs. For example, the anaphase-promoting complex (APC) targets cyclins for degradation at specific cell cycle stages, thereby inactivating CDKs. Additionally, CDK inhibitors (CKIs) such as p21 and p27 can bind to CDK-cyclin complexes and inhibit their activity, providing another layer of regulation. External signals, including growth factors and adhesion molecules, can also modulate CDK regulator activity. Viral proteins can hijack these regulatory mechanisms, as seen with herpes simplex virus type 2.
cyclin-dependent protein serine/threonine kinase regulator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCND1 | Breast cancer, lymphoma | Knockout or overexpression in cancer cell lines |
| CDK7 | Cancer, transcription addiction | Point mutation of kinase domain, inhibitor studies |
| CCNH | Cancer, transcription | Knockout in cancer cells, rescue with wild-type |
| CDK20 | Ciliary disorders | Knockout in Chlamydomonas or mammalian cells |
| CCNE1 | Ovarian cancer, breast cancer | Overexpression in cell lines, xenografts |
Cancer
Dysregulation of cyclin-dependent kinase regulator activity is a hallmark of cancer. Overexpression of cyclins, such as cyclin D1 and cyclin E1, leads to hyperactivation of CDKs and uncontrolled cell proliferation. Mutations in genes encoding CDK regulators or their upstream regulators can also drive tumorigenesis. For instance, CDK7, which is activated by cyclin H, is overexpressed in various cancers and is a target for inhibitors [3,7]. The clinical success of CDK4/6 inhibitors in breast cancer underscores the therapeutic potential of targeting this activity.
Ciliary Disorders
Recent studies have revealed that CDK20/LF2, a cyclin-dependent kinase, activates CDKL5 to control flagellar length. This suggests that regulators of CDK activity may play roles in ciliary and flagellar function. Dysregulation of such processes could contribute to ciliopathies, although direct evidence in human disease is still emerging.
Viral Infections
Viruses can manipulate CDK regulator activity to promote their replication. Herpes simplex virus type 2 infection has been shown to alter CDK activity, potentially to facilitate viral DNA replication or evade host defenses. Understanding these interactions may inform antiviral strategies.
From cyclin-dependent protein serine/threonine kinase regulator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate regulator affect cell cycle progression? | CRISPR knockout in HeLa or HEK293T cells |
| Does a specific point mutation in a cyclin alter CDK binding? | Point mutation knock-in via CRISPR |
| Can a tagged regulator be used to pull down CDK complexes? | Knock-in of FLAG or HA tag |
| Does overexpression of a cyclin drive proliferation? | Overexpression via lentiviral transduction |
| Which genes are essential for CDK regulator activity? | Genome-wide CRISPR library screening |
| How does a regulator affect global transcription? | RNA-seq after knockout or overexpression |
How to Study the cyclin-dependent protein serine/threonine kinase regulator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function phenotype | Identify essential regulators |
| CRISPR point mutation | Effect of specific amino acid change | Dissect binding interfaces |
| Knock-in tagging | Protein localization and interactions | AP-MS, imaging |
| Overexpression | Gain-of-function phenotype | Drive proliferation, test inhibitors |
| RNA-seq | Transcriptional changes | Pathway analysis |
| Kinase assay | Enzymatic activity | Inhibitor screening |
| AP-MS | Protein-protein interactions | Complex composition |
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that are essential for cyclin-dependent kinase regulator activity or that modulate sensitivity to CDK inhibitors. Such screens have been used to uncover novel regulators of the cell cycle and to identify resistance mechanisms.
Biochemical Assays for CDK Activity
In vitro kinase assays using recombinant CDKs and cyclins can directly measure the activity of CDK-regulator complexes. These assays typically use histone H1 or Rb as substrates and detect phosphate incorporation. They are useful for testing inhibitors and for characterizing mutant regulators.
Proteomic and Interactomic Approaches
Affinity purification coupled with mass spectrometry (AP-MS) can identify proteins that associate with CDKs or cyclins, revealing the composition of regulatory complexes. Proximity labeling methods such as BioID can also map interactors in living cells.
Transcriptomic and Functional Genomics
RNA sequencing (RNA-seq) after perturbation of a regulator can reveal downstream transcriptional changes. For example, knockout of CDK7 affects transcription of genes involved in cell cycle and DNA repair. Combining RNA-seq with ChIP-seq can provide insights into direct targets.
How CRISPR Can Be Used to Study GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
Knockout
CRISPR knockout of genes encoding cyclin-dependent kinase regulators, such as CCND1 or CDK7, can abolish their function and reveal their role in cell cycle progression and viability. For example, knockout of CDK7 in cancer cell lines leads to cell cycle arrest and apoptosis, validating it as a therapeutic target. Knockout models are also useful for identifying compensatory mechanisms.
Point Mutation
Introducing specific point mutations into genes like CDK7 or cyclins can dissect the functional importance of individual residues. For instance, mutation of the catalytic lysine in CDK7 abolishes its kinase activity, while mutation of the cyclin-binding domain prevents complex formation. Such models help distinguish between kinase-dependent and independent functions.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins (e.g., GFP) into endogenous loci allows for real-time tracking and biochemical isolation of CDK-regulator complexes. This approach has been used to study the dynamics of CDK1-cyclin B complexes during mitosis.
Overexpression
Overexpression of cyclins or CDKs via CRISPR activation (CRISPRa) or lentiviral delivery can mimic the overexpression seen in cancers. For example, overexpression of cyclin D1 drives cell proliferation and can transform cells. Overexpression models are valuable for testing targeted inhibitors.
How EDITGENE Supports cyclin-dependent protein serine/threonine kinase regulator activity Research
Researchers studying cyclin-dependent protein serine/threonine kinase regulator activity-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for cyclin-dependent protein serine/threonine kinase regulator activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CCND1 Knockout HEK293 Cell Line | EDC07534 | Human | 595 | Details Get a Quote |
| CCNE2 Knockout HEK293 Cell Line | EDJ-KQ252 | Human | 9134 | Details Get a Quote |
| CCND3 Knockout HEK293 Cell Line | EDJ-KQ285 | Human | 896 | Details Get a Quote |
| CCND2 Knockout HEK293 Cell Line | EDJ-KQ884 | Human | 894 | Details Get a Quote |
| CCNB2 Knockout HEK293 Cell Line | EDJ-KQ1532 | Human | 9133 | Details Get a Quote |
| CCNB3 Knockout HEK293 Cell Line | EDJ-KQ1533 | Human | 85417 | Details Get a Quote |
| CCNG2 Knockout HEK293 Cell Line | EDJ-KQ1534 | Human | 901 | Details Get a Quote |
| CCNA1 Knockout HEK293 Cell Line | EDJ-KQ1867 | Human | 8900 | Details Get a Quote |
| CCNT1 Knockout HEK293 Cell Line | EDJ-KQ2254 | Human | 904 | Details Get a Quote |
| CCNL2 Knockout HEK293 Cell Line | EDC90276 | Human | 81669 | Details Get a Quote |
| CCNI Knockout HEK293 Cell Line | EDJ-KQ3086 | Human | 10983 | Details Get a Quote |
| CCNT2 Knockout HEK293 Cell Line | EDJ-KQ3510 | Human | 905 | Details Get a Quote |
| CCNG1 Knockout HEK293 Cell Line | EDJ-KQ3523 | Human | 900 | Details Get a Quote |
| CCNE1 Knockout HEK293 Cell Line | EDC07535 | Human | 898 | Details Get a Quote |
| CCNC Knockout HEK293 Cell Line | EDJ-KQ4205 | Human | 892 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About cyclin-dependent protein serine/threonine kinase regulator activity
What is GO:0016538?
GO:0016538 is the Gene Ontology term for cyclin-dependent protein serine/threonine kinase regulator activity, a molecular function that modulates the activity of CDKs through association with cyclins and other proteins.
What genes are involved in cyclin-dependent protein serine/threonine kinase regulator activity?
Key genes include cyclins (CCNA1, CCNB1, CCND1, CCNE1, CCNH) and CDKs (CDK1, CDK7, CDK20), as well as regulatory subunits like CKS1B and MNAT1 [1,3,4,7].
How does cyclin-dependent kinase regulation work?
Regulatory subunits bind to CDKs, inducing conformational changes that activate or inhibit kinase activity, often in response to cell cycle signals.
Why is CDK regulation important in cancer?
Dysregulated CDK activity drives uncontrolled proliferation; thus, targeting CDK regulators is a promising anticancer strategy [1,3].
What diseases are associated with CDK regulator dysfunction?
Cancer is the most prominent, but ciliary disorders and viral infections may also involve CDK regulators [1,4,8].
What methods are used to study CDK regulators?
CRISPR knockout, point mutation, knock-in tagging, overexpression, RNA-seq, and biochemical kinase assays are commonly used [1,6].
What is the role of CDK7?
CDK7, activated by cyclin H, is part of the CAK complex that phosphorylates other CDKs and regulates transcription; it is a target for cancer therapy [3,7].
Can CDK regulators be targeted therapeutically?
Yes, inhibitors of CDK4/6 and CDK7 are in clinical trials or approved for certain cancers [1,3].
What is the connection between CDK20 and cilia?
CDK20/LF2 activates CDKL5 to control flagellar length, linking CDK regulation to ciliary function.
How can EDITGENE help my research on CDK regulators?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression models, and library screening services to study CDK regulator genes.
Conclusion
GO:0016538, cyclin-dependent protein serine/threonine kinase regulator activity, is a central molecular function that controls cell cycle progression and transcription. Its dysregulation is implicated in cancer and other diseases, making it a prime target for therapeutic intervention. Advances in CRISPR technology now allow precise manipulation of genes encoding CDK regulators, enabling detailed mechanistic studies and drug discovery. EDITGENE offers a comprehensive portfolio of CRISPR services to support research in this vital area.
References
- 1. Otto T et al.. 2017. Cell cycle proteins as promising targets in cancer therapy.. Nat Rev Cancer 17(2):93-115 PMID: 28127048
- 2. Massacci G et al.. 2023. The Cyclin-dependent kinase 1: more than a cell cycle regulator.. Br J Cancer 129(11):1707-1716 PMID: 37898722
- 3. Kovalová M et al.. 2023. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).. Expert Opin Ther Pat 33(2):67-87 PMID: 36975020
- 4. Hou Y et al.. 2025. Activation of the ciliary kinase CDKL5 is mediated by the cyclin-dependent kinase CDK20/LF2 to control flagellar length.. PLoS Biol 23(12):e3003560 PMID: 41385589
- 5. Symington BE. 1992. Fibronectin receptor modulates cyclin-dependent kinase activity.. J Biol Chem 267(36):25744-7 PMID: 1464591
- 6. Davies TG et al.. 2002. Structure-based design of cyclin-dependent kinase inhibitors.. Pharmacol Ther 93(2-3):125-33 PMID: 12191605
- 7. Shuttleworth J. 1995. The regulation and functions of cdk7.. Prog Cell Cycle Res 1:229-40 PMID: 9552366
- 8. Hossain A et al.. 1997. Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.. J Gen Virol 78 ( Pt 12):3341-8 PMID: 9400986
